Sucampo Pharmaceuticals, Inc. (SCMP) is surging over 10% to $16.52 in pre-market trading Wednesday after it reported fiscal results for the fourth quarter.
In its quarterly report, the biopharmaceutical firm said it earned $0.21 per share, non-GAAP, in-line with what Wall Street was expecting. Revenue rose 54.3% on a yoy basis to $37.8 million, but missed views for $39.91 million.
For full-year 2014, the company reported total revenues of $115.5 million compared to $89.6 million in the same period in 2013.
For FY15, SCMP provided EPS guidance of $0.55-$0.65 versus consensus of $0.62 per share. Sucampo said it expects full year 2015 GAAP net income to be in the range of $25 million to $30 million.
On valuation measures, Sucampo Pharmaceuticals Inc. Cl A shares, which currently have an average 3-month trading volume of 307,542 shares, trade at a trailing-12 P/E of 116.05, a forward P/E of 24.95 and a P/E to growth ratio of 0.42. The median Wall Street price target on the name is $18.00 with a high target of $20.00. Currently ticker boasts 4 ‘Buy’ endorsements, compared to 1 ’Hold’ and no ‘Sell’.
Profitability-wise, SCMP has a t-12 profit and operating margin of 5.56% and 18.42%, respectively. The $655.76 million market cap company reported $110 million in cash vs. $48.08 million in debt in its most recent quarter.
SCMP currently prints a one year return of about 76.33% and a year-to-date return of around 4.83%.
Sucampo Pharmaceuticals Inc. focuses on the research, discovery, development, and commercialization of proprietary drugs based on prostones and other drug technologies in the Americas, Europe, and Asia. The company was founded in 1996 is headquartered in Bethesda, Maryland.